ʻAʻohe ala ʻike ʻia e nā kauka e pale ai i ka maʻi o Parkinson. Eia naʻe, eia ka mea i hōʻike ʻia e ka noiʻi.

ʻO nā kāne e ʻai ana i nā mea inu caffeinated maʻalahi (kofe, ti, cola) (1 a 4 mau kīʻaha i kēlā me kēia lā) hiki ke pōmaikaʻi mai kahi hopena pale i ka maʻi o Parkinson, e like me nā haʻawina cohort mai nā ʻēheu nui1,2,11,12. ʻO kahi haʻawina i hana ʻia ma luna o ka heluna kanaka o ka poʻe Kina i hōʻike i ka hopena like34. Ma ka ʻaoʻao ʻē aʻe, i nā wahine, ʻaʻole i hōʻike maopopo ʻia ka hopena pale. ʻO ke ʻano like, ʻike ʻia kahi noiʻi cohort 18 makahiki i ka emi ʻana o ka pilikia o ka maʻi o Parkinson i nā mea hoʻohana kofe i lawe ʻole i ka lāʻau hoʻololi hormone i ka wā menopause. ʻO ka mea ʻē aʻe, ʻo ka lawe pū ʻana i ka lāʻau lapaʻau homoni a me ka caffeine e hoʻonui i ka pilikia.13

ʻO ka inu ʻana i hoʻokahi a ʻehā mau kīʻaha kī ʻōmaʻomaʻo i ka lā e pale aku i ka maʻi o Parkinson, kahi hopena i manaʻoʻiʻo ʻia ke kumu, ma ka liʻiliʻi loa, i ka loaʻa ʻana o ka caffeine i loko o ke kī ʻōmaʻomaʻo. No nā kāne, ʻo ka loaʻa ʻana o ka hopena maikaʻi loa mai ka 400 mg a i ka 2,5 g o ka caffeine i kēlā me kēia lā, a i ʻole ka liʻiliʻi o 5 mau kīʻaha kī ʻōmaʻomaʻo i kēlā me kēia lā.

Eia kekahi, ʻoi aku ka liʻiliʻi o ka poʻe i hoʻohui i ka paka i ka maʻi Parkinson. Wahi a kahi meta-analysis i paʻi ʻia ma 2012, ua hoʻemi ʻia kēia pilikia e 56% i ka poʻe puhi paka, ke hoʻohālikelike ʻia me ka poʻe ʻaʻole i puhi. Hoʻoulu ʻo Nicotine i ka hoʻokuʻu ʻana o ka dopamine, no laila e uku ai i ka deficit dopamine i loaʻa i nā maʻi. Eia naʻe, ʻaʻole paona nui kēia pōmaikaʻi i ka hoʻohālikelike ʻia me nā maʻi āpau e hiki ke hoʻoulu ʻia i ka puhi paka, ʻoi aku ka nui o nā ʻano maʻi kanesa.

Hōʻike kekahi mau meta-analyze e pili ana ka ibuprofen me ka hōʻemi ʻia o ka maʻi o Parkinson. Kūʻē ka ʻikepili no nā lāʻau anti-inflammatory nonsteroidal (NSAIDs), me ka ʻike ʻana o kekahi mau meta-analyses e pili ana nā NSAID me ka hōʻemi ʻana o ka pilikia o ka maʻi ʻoiai ʻo nā mea ʻē aʻe i hōʻike ʻole i kahi hui nui.